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ABSTRACT
Objective To evaluate the decrease of cartilage 
destruction by a novel orally active and specifi c matrix 
metalloproteinase 13 (MMP-13) inhibitor in three different 
animal models of rheumatoid arthritis (RA).
Materials and methods The SCID mouse 
co-implantation model of RA, the collagen-induced 
arthritis (CIA) model in mice and the antigen-induced 
arthritis model (AIA) in rabbits were used.
Results In the SCID mouse co-implantation model, 
the MMP-13 inhibitor reduced cartilage destruction 
by 75%. In the CIA model of RA, the MMP-13 inhibitor 
resulted in a signifi cant and dose-dependent decrease in 
clinical symptoms as well as of cartilage erosion by 38% 
(30 mg/kg), 28% (10 mg/kg) and 21% (3 mg/kg). No 
signifi cant effects were seen in the AIA model. No toxic 
effects were seen in all three animal models.
Conclusion Although several MMPs in concert with 
other proteinases have a role in the process of cartilage 
destruction, there is a need for highly selective MMP 
inhibitors to reduce severe side effects that occur with 
non-specifi c inhibitors. Signifi cant inhibition of MMP-13 
reduced cartilage erosions in two of three tested animal 
models of RA. These results strongly support the 
development of this class of drugs to reduce or halt joint 
destruction in patients with RA.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂ amma-
tory disease characterised by persistent inﬂ amma-
tory reactions in the joints resulting in a progressive 
articular destruction associated with the loss of joint 
function and disability.1 Matrix metallo proteinases 
(MMPs) are a family of secreted or transmembrane 
zinc-dependent endoproteinases that are responsi-
ble for the degradation of cartilage in arthritides.2 3 
MMP-1 and MMP-13 are powerful collagenolytic 
enzymes, cleaving type II collagen. In addition, 
MMP-13 cleaves also other cartilage collagen types 
such as types IX and X4 5 and other extracellu-
lar matrix components like ﬁ bronectin, aggrecan 
and small leucine-rich repeat proteoglycans like 
ﬁ bromodulin.6
In this study, we analysed a novel highly selec-
tive MMP-13 inhibitor which differs from previ-
ous MMP inhibitors, because it does not bind to 
the catalytic zinc ion and is non-competitive with 
respect to substrate binding.7 Unlike other MMP 
inhibitors this novel MMP-13 inhibitor binds deeply 
into the S1′ pocket and interacts with residues in 
the MMP-13 speciﬁ city loop to gain remarkable 
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selectivity. The feasibility of the oral application 
of this MMP inhibitor was previously tested and 
reached efﬁ cient plasma levels in animals.7 We 
used the SCID-mouse co-implantation model of 
RA, the collagen-induced arthritis (CIA) model in 
mice and the antigen-induced arthritis (AIA) model 
in rabbits, to analyse the effects of this highly selec-
tive MMP-13 inhibitor on the process of cartilage 
invasion and destruction in RA.
MATERIALS AND METHODS
Patients and materials
Normal human articular cartilage and RA syno-
vial tissue biopsy specimens were obtained from 
patients undergoing joint replacement surgery at 
the Department of Orthopedic Surgery, Schulthess 
Clinic Zurich, Switzerland. All patients with RA 
fulﬁ lled the American College of Rheumatology 
criteria for the classiﬁ cation of RA.8 The MMP-13 
selective inhibitor used in this study is described as 
Compound 2 in a recent publication.7
Immunohistochemistry
Monoclonal mouse anti-human MMP-13 antibod-
ies (Calbiochem, Nottingham, UK) or monoclonal 
mouse MMP-1 antibodies (R&D Systems, Rotkreuz, 
Switzerland) were used for immunohistochemistry 
as described in the online supplementary material.
SCID mouse co-implantation experiments and 
histological evaluation
Implantation of RA synovial ﬁ broblasts (RASF) 
together with normal human cartilage was performed 
as described in the supplementary material.9 The 
oral administration of the speciﬁ c MMP-13 inhibi-
tor (60 mg/kg/day, provided by Pﬁ zer, Ann Arbor, 
Michigan, USA) started on day 1 after surgery 
continuing through day 60.7 A histological evalua-
tion was performed using a semiquantitative score 
for invasion as previously described.9
Collagen-induced arthritis
CIA was induced in DBA/1LacJ female mice 
(n=42) as described in the supplementary mate-
rial. Beginning on day 27 after immunisation, the 
mice were treated twice a day by oral gavages 
with vehicle or vehicle containing compound at 
3, 10 or 30 mg/kg/day continuing through day 42. 
The score grading system for the clinic and the 
erosion of the joints is described in the supple-
mentary material.
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
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Antigen-induced arthritis
Oral dosing of the speciﬁ c MMP-13 inhibitor (30 mg/kg, twice 
a day) started 1 h before the adult male speciﬁ c-pathogen free 
New Zealand white rabbits were immunised as described in the 
supplementary material. After 12 days the animals were killed. 
To score cartilage erosions toluidine blue stained slides of the 
joints were evaluated and the concentration of proteoglycan per 
mg cartilage was determined as described by Farndale et al.10
Statistics
The Mann–Whitney U test was used for comparison of medians 
from independent samples, in all cases, p<0.05 was considered 
as signiﬁ cant.
RESULTS
Expression of MMP-13 and MMP-1 in the invasion process 
mediated by RASF
MMP-13 was highly expressed in human RA synovium at sites of 
cartilage invasion. In addition, all explants from the SCID-mouse co-
implantation model showed expression of MMP-13 in ﬁ broblasts 
around the explants as well as in chondrocytes of the implanted 
cartilage. In addition, MMP-1 was highly expressed in the explants 
from the SCID-mouse co-implantation model (ﬁ gure 1A–F).
Effects of the MMP-13 inhibitor on the SCID-mouse model of RA
To investigate the effects of the speciﬁ c MMP-13 inhibitor on car-
tilage erosion caused by RASF, the SCID-mouse co- implantation 
model of RA was used. The MMP-13 inhibitor was adminis-
tered orally for 60 days (60 mg/kg/day) without any toxic side 
effects considering behaviour and weight. As expected, human 
RASF in mice receiving placebo food tablets invaded deeply into 
the co-implanted normal human cartilage (ﬁ gure 2A,B; invasion 
score: 4.00±0.52, n=4). Most interestingly, treatment of mice 
with the speciﬁ c MMP-13 inhibitor signiﬁ cantly decreased the 
invasiveness of RASF into the cartilage (ﬁ gure 2C,D; invasion 
score: 0.98±0.24; p<0.001, n=4). In this model, cartilage inva-
sion by RASF was decreased by 75.5% by the speciﬁ c MMP-13 
inhibitor (ﬁ gure 3). In conclusion, the highly selective MMP-13 
inhibitor signiﬁ cantly decreased the invasion of human RASF 
into human cartilage over 60 days.
Effects of the MMP-13 inhibitor in CIA
For CIA in mice the speciﬁ c MMP-13 inhibitor was administered 
orally at 3, 10 and 30 mg/kg without any toxic side effects. By 
analysing each limb, a clinical score was obtained for the treated 
and control animals. Non-immunised and non-treated animals 
did not develop any clinical signs of arthritis (normal, ﬁ gure 4A). 
Immunised and lipopolysaccharide-treated animals served as 
positive controls and developed severe clinical signs of arthritis 
(vehicle, ﬁ gure 4A). Immunised and lipopolysaccharide-treated 
animals treated with the speciﬁ c MMP-13 inhibitor showed a 
dose-dependent and signiﬁ cant decrease of clinical signs of arthri-
tis (30 mg/kg: p=0.01; 10 mg/kg: p=0.05). The lowest dosage of 
3 mg/kg showed no signiﬁ cant effects (ﬁ gure 4A). By evaluation 
of the mean erosion score the MMP-13 inhibitor decreased dose 
Figure 1 Expression of matrix metalloproteinase 13 (MMP-13) in 
human rheumatoid arthritis (RA) (A) synovial tissue (magnifi cation ×200) 
and (B) the isotype control (magnifi cation ×200). Arrows indicate the 
expression of MMP-13 at sites of cartilage destruction. Expression 
of MMP-13 in the explants of the SCID-mouse co-implantation model 
of (C) RA (magnifi cation ×400) and (D) the isotype control staining 
(magnifi cation ×400). Expression of (E) MMP-1 (magnifi cation ×400) 
and (F) the isotype control staining (magnifi cation ×400).
Figure 2 Effects of the specifi c matrix metalloproteinase 13 
(MMP-13) inhibitor in the SCID mouse co-implantation model of 
rheumatoid arthritis (RA; 60 mg/kg/day). (A,B) Representative images 
of the histological analysis of haematoxylin and eosin stained slides 
of the SCID mouse co-implantation model of RA. RASF invaded the 
co-implanted cartilage deeply in animals treated with placebo pellets as 
indicated by the arrows (A, magnifi cation ×400 and B, magnifi cation 
×600). (C,D) Animals treated orally with the highly specifi c MMP-13 
inhibitor did not show cartilage invasion (C, magnifi cation ×200 and D, 
magnifi cation ×100). C, cartilage.
Figure 3 Histological evaluation of the in vivo effects of the specifi c 
matrix metalloproteinase 13 (MMP-13) inhibitor in the SCID mouse 
co-implantation model of rheumatoid arthritis (RA; n=4 for each 
group). The specifi c MMP-13 inhibitor decreased cartilage invasion by 
75%. ∗p≤0.05.
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(ﬁ gures 4B and 5). In conclusion, the selective MMP-13 inhibitor 
decreased clinical signs of arthritis and cartilage erosions in CIA.
Effects of the MMP-13 inhibitor in AIA
To examine the inhibition of cartilage erosion by the MMP-13 
inhibitor we developed AIA in rabbits. The oral application of 
the MMP-13 inhibitor (30 mg/kg/day) did not induce any side 
effects in the animals. To evaluate the break down of the carti-
lage, the concentration of proteoglycan of the joints was eval-
uated. The induction of AIA in untreated animals resulted in a 
signiﬁ cant loss of proteoglycans of the joints (positive control, 
proteoglycan ng/mg cartilage ± SEM: 112.4±6.6 to 82.2±4.8). 
However, the speciﬁ c MMP-13 inhibitor did not signiﬁ cantly 
decrease the loss of proteoglycans (91.2±6.2; ﬁ gure 6A). The 
histological analysis of the cartilage erosions showed an inhi-
bition by 14%, but not signiﬁ cant, in animals treated with the 
speciﬁ c MMP-13 inhibitor (ﬁ gure 6B). In conclusion, in contrast 
to the other two animal models of arthritis, the MMP-13 inhibi-
tor did not show signiﬁ cant effects in the AIA model.
DISCUSSION
In this study, we evaluated the effects of a novel MMP-13 inhib-
itor on cartilage and joint destruction using different models of 
Figure 6 Effects of the specifi c matrix metalloproteinase 13 (MMP-13) 
inhibitor (30 mg/kg/day) in the antigen-induced arthritis (AIA) model 
in rabbits (normal rabbits n=2, arthritic animals (=vehicle) n=6, 
MMP-13 inhibitor treated n=7). The induction of AIA in untreated 
animals served as a positive control. (A) Treatment with the MMP-13 
inhibitor did not signifi cantly decrease the loss off proteoglycan. (B) The 
histological analysis of the cartilage erosions showed a non-signifi cant 
downregulation of erosions by 14% in animals treated with the MMP-13 
inhibitor.
Figure 4 Effects of the specifi c matrix metalloproteinase 13 (MMP-13) inhibitor in the collagen-induced arthritis model. Clinical scoring was carried 
out as described in the ‘Material and methods’ section. Non-immunised and non-treated animals were used as negative control (‘normal’; n=2). 
Immunised and lipopolysaccharide (LPS)-treated animals served as positive controls (‘vehicle’, n=10). (A) Immunised and LPS-treated animals given 
orally the highly specifi c MMP-13 inhibitor (n=10 each group) showed a dose-dependent and signifi cant reduction of clinical signs of arthritis. A mean 
erosion score was evaluated by analysing toluidine blue stained slides. (B) The highly selective MMP-13 inhibitor decreased dose dependently the 
destruction process of the joints by 21–38%. ∗p≤ 0.05; ∗∗p=0.01.
Figure 5 Toluidine blue stained slides from the collagen-induced arthritis model. Representative joint from animals treated for 42 days with the 
specifi c (A) matrix metalloproteinase 13 inhibitor (30 mg/kg) and (B) control animals (vehicle) and (C) non-immunised and non-treated animals 
(normal). Arrow indicates healthy cartilage in the non-immunised and non-treated animals. Magnifi cation ×50.
dependently the destruction process of the joints (ﬁ gure 4B). Clear 
effects were seen even with the lowest dose of 3 mg/kg, result-
ing in 21% decrease of destruction, and with 10 mg/kg result-
ing in 28% reduction of destruction. A signiﬁ cant inhibition of 
joint erosion by 38% could be observed with 30 mg/kg, p<0.05 
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RA—the SCID mouse co-implantation model, the CIA model 
and the AIA model. We are aware that animal models cannot 
reﬂ ect the complexity of any human disease. Therefore, we 
used three different models of RA since each model is focused 
on a speciﬁ c process within the disease and does not display 
the whole spectrum of pathological changes that occur in 
humans.11 12 We used the CIA and the AIA model, which are 
strongly driven by inﬂ ammation. Moreover, we analysed the 
effects of the MMP-13 inhibitor on human cells using the SCID 
mouse co-implantation model. This focuses speciﬁ cally on the 
invasion of human RASF into human cartilage and is there-
fore relevant for the analysis of processes that interfere with 
destruction.13 The speciﬁ c MMP-13 inhibitor decreased carti-
lage destruction in both, the SCID mouse and the CIA model. 
In the AIA model, the MMP-13 inhibitor did not show a signif-
icant effect on the destruction process. Both the CIA and the 
AIA are animal models in which proinﬂ ammatory processes 
have a major role, which are associated with excessive expres-
sions of other matrix degrading enzymes. This might explain 
why the speciﬁ c MMP-13 inhibitor was more effective in the 
non-inﬂ ammatory SCID mouse co-implantation model.
Collagenase-1 (MMP-1) also has a key role in the process of 
cartilage destruction in RA. It has been shown that inhibition of 
MMP-1 by ribozymes has a protective effect on cartilage ero-
sion in the SCID mouse co-implantation model.14 Both MMP-1 
and MMP-13 contribute to the process of cartilage destruction 
in RA and can therefore be targeted for treatment. However, 
MMP-13 is ﬁ ve times more effective at degrading collagen type 
II than MMP-1,15 suggesting that small changes in the expres-
sion level of MMP-13 may have severe consequences for the 
cartilage integrity. Cleaved fragments of collagen type II again 
can further induce MMP-13 gene expression and result in a cycle 
of collagen degradation.
The analysis of MMP-1 in mouse and rabbit models of arthri-
tis is problematic because MMP-1 is present in rabbits and 
humans, but functionally absent in mice, whereas MMP-13 is 
present in all.16 17 Murine collagenase-like A (McolA) and McolB 
are counterparts of the human interstitial collagenase (MMP-1) 
with a high percentage of identities (58% in amino acids and 
74% in nucleotides) but only present during mouse embryogen-
esis. Recombinant McolA displays proteolytic activity against 
type I and type II ﬁ brillar collagens, although its speciﬁ c activity 
versus ﬁ brillar type I collagen is much lower than that described 
for human MMP-1. McolB is apparently devoid of collagenolytic 
activity.18 Thus, we cannot exclude the possibility that the miss-
ing effect of the MMP-13 inhibitor in the AIA model is due to 
the induction of MMP-1 in a highly inﬂ ammatory milieu. Since 
in the non-inﬂ ammatory SCID mouse model, MMP-1 is only 
expressed constitutively by the implanted human cells, this 
might account for the higher efﬁ ciency of the MMP-13 inhibitor 
in this model. Even though MMP-13 in rabbits is 90% and in 
mouse is 86% homologous to the human MMP-13 protein, it 
might be possible that the inhibitor designed against the human 
MMP-13 cannot inhibit the collagenases of other species to the 
same extent.17
The majority of previously developed MMP inhibitors 
are non-speciﬁ c and inhibit a large number of MMPs. Broad-
spectrum MMP inhibitors based on hydroxamate, a chemical 
chelator that does not show speciﬁ city for zinc, are known to 
have severe side effects due to inhibition of non-target metallo-
proteinases. The new mode of action of our MMP inhibitor has 
the advantage of targeting single MMPs in a highly speciﬁ c man-
ner. Therefore, it is likely that side effects like painful joint stiff-
ening due to musculoskeletal syndrome do not occur.7
Recently, newly developed MMP inhibitors have comprised 
piperazine-based hydroxamic acids, and carboxylic and phos-
phinic acids, but the drawback of these inhibitors is that they 
are not selective for MMP-13 and that they have a short half-
life in vivo.19–21 Only a few of the previously developed MMP 
inhibitors reached the clinical testing phases but none of these 
is speciﬁ c for MMP-13. In RA, the MMP inhibitor Trocade 
(Hoffmann-La Roche, Basel, Switzerland) with selectivity for the 
collagenase MMP-1 and the gelatinases (MMP-2 and MMP-9) 
was not efﬁ cacious.3 Another MMP-inhibitor BB-2827 (British 
Biotech, Oxford, UK) a collagenase-targeting hydroxamate, was 
studied in clinical phase I.22 To date, only the non-chelating 
MMP-13 inhibitor from Alantos Pharmaceuticals (Heidelberg, 
Germany) has reached preclinical testing phase.11
Physiologically MMP-13 activity is controlled by naturally 
occurring inhibitors such as α-macroglobulins and tissue inhibi-
tors of metalloproteinases.20 23 However, these natural inhibi-
tors do not speciﬁ cally inhibit MMP-13 to the extent that would 
be necessary for therapeutic intervention.
In normal human tissues, MMP-13 is scarcely detected, but it 
has a pivotal role in the pathogenesis of RA and osteoarthritis.24 
MMP-13 is synthesised as a pro-enzyme and must be processed 
by proteolytic cleavage at the N-terminus to generate the active 
form. In vivo, MMP-14 (MT1-MMP) and MMP-2 (gelatinase 
A) are two of several enzymes responsible for the activation of 
proMMP-13 and both are overexpressed in RA. In transgenic 
mice, excessive MMP-13 activity can result in articular cartilage 
degradation.25 In RA synovial tissues, MMP-13 is detected in 
ﬁ broblasts, chondrocytes, macrophages and vascular endothe-
lial cells.26–28 Most importantly, MMP-13 is detected at sites of 
joint destruction.29 30
To analyse the anti-destructive effects of this novel MMP-13 
inhibitor, we decided to use a prophylactic approach for all 
three animal models and therefore we applied the drug before 
the appearance of the disease, which provides more information 
about the pathogenesis of the disease.
In RA, joint damage is often considered to be a direct result of 
the inﬂ ammatory synovitis.3 Thereby, the synovial ﬁ broblasts 
keep an activated status mediated by the inﬂ ammatory milieu 
and continuously express matrix degrading enzymes and/or 
activate other cells like chondrocytes, resulting in enhanced 
destruction of the cartilage.31 This implies that by actively treat-
ing the synovial inﬂ ammation, subsequent joint damage would 
be reduced and the long-term outcome of patients with RA 
would improve. We observed that the speciﬁ c MMP-13 inhibitor 
was effective in destructive models but less effective in inﬂ am-
matory models. An alternative is that the mechanisms causing 
inﬂ ammation and those leading to joint destruction are paral-
lel processes, but only indirectly related. Clinical studies show 
that radiological progression of RA occurs in spite of reduction 
in serological markers of inﬂ ammation.32 33 Experimental stud-
ies also fail to show a close correlation between inﬂ ammation 
and cartilage damage.34 35 Attempts to improve the outcome of 
RA should not merely concentrate on controlling inﬂ ammation, 
but should also aim to reduce the associated connective tissue 
damage. Therefore, there is a true need for the development 
of additional anti-destructive drugs such as selective MMP-13 
inhibitors—that may target speciﬁ cally activated synovial 
ﬁ broblasts.
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